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Abstract
Osteoporosis is a disease characterized by low bone mass, most commonly caused by an increase in 
bone resorption that is not matched by sufficient bone formation. The most common complications of 
postmenopausal osteoporosis are bone-related defects and fractures. Fracture healing is a multifactorial 
bone regeneration process, influenced by both biological and mechanical factors related to age, osteoporosis 
and stability of the osteosynthesis. During the treatment of bone defects in osteoporotic conditions, 
imbalanced bone remodeling is the leading cause for implant failure. To overcome these problems, ethyl-2,5-
dihydroxybenzoate (E-2,5-DHB), a drug that promotes bone formation and inhibits bone resorption, was used. 
E-2,5-DHB-incorporating titanium (Ti) implants using poly(lactic-co-glycolic acid) (PLGA) coating for local 
delivery of E-2,5-DHB were developed and the effects on bone healing of femoral defects were evaluated in 
an osteoporotic model. The release of E-2,5-DHB resulted in decreased bone resorption and increased bone 
formation around the implant. Thus, it was confirmed that, in the osteoporotic model, bone healing was 
increased and implant fixation was enhanced. These results suggested that E-2,5-DHB-coated Ti implants 
have great potential as an ultimate local drug delivery system for bone tissue scaffolds.
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Introduction
Osteoporosis is a global emerging healthcare 
issue and a socio-economic problem characterized 
by reduced bone mass, weak bone strength and 
microarchitectural aggravation in the cortical 
and trabecular skeleton. These features lead to 
skeletal fragility and sensitivity to fractures. 
Osteoporosis is an age-related disease caused by a 
disproportion between osteogenic bone formation 
and osteoclastic bone resorption, which is often the 
result of postmenopausal estrogen deficiency (Pei and 
Tontonoz, 2004; Rodan and Martin, 2000).
 In recent years, fracture healing has been widely 
studied, but less attention has been placed on 
osteoporotic fractures. Since osteoporosis-related 
fractures generally occur at long bone sites subjected 
to loading stress, mechanical intervention may 
affect the healing process. A few studies report the 
therapeutic effect of local implantation of biomimetic 
scaffolds during osteoporotic defect regeneration 
(Cheng et al., 2013; Zhang et al., 2012). Fractures 
of osteoporotic bones present diverse challenges, 
including a large proportion of fixation failure 
and impaired healing capability, which make their 
medical management challenging (Kyllönen et 
al., 2015). Osteoporotic bone fracture, not implant 
breakage, is the primary cause of failure of internal 
fixation. Because bone mineral density associates with 
the ability to hold screws, osteoporotic bone often 
lacks the strength to hold plates and screws securely 
(Alho, 1993; Sjostedt et al., 1994; Strømsøe et al., 1993). 
The major challenges in the treatment of osteoporotic 
fractures are stable internal fixation, without implant 
loosening, and subsequent successful bone healing. 
However, alterations in bone turnover, bone tissue 
quality and delays in fracture healing are some of 
the well-known key issues that must be addressed 
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by clinicians and researchers to improve treatment 
outcomes for patients with osteoporotic fractures 
(Barrios et al., 1993; Gardner, 2004).
 The discovery of osteopromotive and inductive 
agents, with the potential to stimulate bone formation, 
has raised hope for the augmentation of osteoporotic 
fracture healing. Local release of a bone anabolic 
agent at the site of an osteoporotic fracture would 
potentially facilitate a rapid increase in bone strength 
and quality, as well as reduce the bone healing 
period and prevent the development of problematic 
non-union. Local delivery is expected to increase the 
utility and efficacy of bone anabolic or antiresorptive 
drugs and decrease adverse effects related to their 
systemic administration.
 Ethyl-2,5-dihydroxybenzoate (E-2,5-DHB) 
is a derivative of ethyl-3,4-dihydroxybenzoate 
(E-3,4-DHB), which is an element of the Rubus 
coreanus extract. Rubus coreanus total extract is a 
natural bioactive substance with bone-protective 
effects during postmenopausal osteoporosis in 
ovariectomized rats (Do et al., 2008). A natural 
bioactive substance, it has been considered as a 
biomedical material due to its good biocompatibility 
and various bio-active characteristics. E-3,4-DHB 
also improves osteoinductive activity by stimulating 
osteoblast differentiation and reduces bone resorption 
by inhibiting osteoclast differentiation (Kwon et al., 
2014). However, the effect of E-2,5-DHB on bone 
healing in osteoporotic conditions has yet to be 
clearly defined. Therefore, it was hypothesized that 
E-2,5-DHB, with its dual effects on osteoblasts and 
osteoclasts, would promote bone defect healing in an 
osteoporotic model.
 Titanium (Ti) and its alloys are extensively used 
as implant materials in the orthopedic and dental 
fields because of their excellent biocompatibility and 
mechanical properties (Long et al., 1998). Ti facilitates 
new bone formation and provides long-lasting bone-
implant stability (Ravichandran et al., 2012). Ti and 
its alloys are widely used as hard tissue replacements 
in artificial bones, joints and dental implants. 
As these types of replacements, their low elastic 
modulus is generally viewed as a biomechanical 
advantage because they can produce smaller stress 
shielding (Sáenz de Viteri and Fuentes, 2013). If 
several interconnected pores are introduced into Ti 
and its alloys, their elastic modulus decreases to a 
level similar to that of cancellous bone (Pattanayak 
et al., 2011). Porous bone scaffolds can be made by 
a variety of methods and selective laser melting 
(SLM) processes are used to produce porous bone 
substitutes (Mullen et al., 2009; Stamp et al., 2009; 
Thijs et al., 2010).
 Our previous study reports whether E-2,5-DHB 
can be an effective material and whether it plays a role 
in inducing osteoblast differentiation and inhibiting 
osteoclast differentiation (Kwon et al., 2016). In the 
treatment of bone defects in osteoporotic conditions, 
imbalanced bone remodeling is the leading cause 
of implant failure. To overcome these problems, 
E-2,5-DHB, a drug that promotes bone formation 
and inhibits bone resorption, was used. In this 
study, an E-2,5-DHB-incorporating Ti implant using 
poly(lactic-co-glycolic acid) (PLGA) coating for local 
delivery of E-2,5-DHB was developed and its effects 
on bone healing of femoral defects in an osteoporotic 
rat model were evaluated.
Materials and Methods
Materials
The PLGA polymer (polylactic acid/polyglycolic 
acid = 50/50) was obtained from Evonik (Birmingham, 
AL, USA). Acetone was obtained from Duksan Pure 
Chemicals Co., Ltd (Kyungki Do, Korea). E-2,5-
DHB was supplied by Cell Safe Ltd. (Kyungki Do, 
Korea). MC3T3-E1 mouse preosteoblast cells were 
purchased from Riken BRC cell bank (Tokyo, Japan). 
α-modification minimum essential medium (α-MEM) 
and fetal bovine serum (FBS) were obtained from 
WelGENE (Daegu, Korea). Bradford assay kit was 
purchased from Bio-Rad (Hercules, CA, USA).
Three-dimensional printed porous titanium 
implants containing E-2,5-DHB
Three-dimensional (3D) printed porous Ti implants 
were produced by a powder bed fusion (PBF) metal 
3D printer (SLM system: Metasys250; Winforsys, 
Kyungki Do, Korea) using Ti powder (Ti-6Al-4V; 
LPW-Ti64Gd5; LPW Technology Ltd., Sci-Tech, 
Fig. 1. Schematic diagram indicating the surgery time points for rats in the sham surgery (SHAM) and 
ovariectomy (OVX) groups. 6 weeks after ovariectomy, establishment of the osteoporotic model was 
confirmed in the OVX rats, using SHAM rats as control. Also at 6 weeks, femur defect drilling was 
performed in the OVX rats, followed by implantation with 3D printed Ti implants. After 4, 8 and 12 
weeks, OVX rats were sacrificed and femur specimens were removed for assessment.
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Daresbury, UK). The Ti implants were manufactured 
using an SLM system (Metasys250; Winforsys). 
This system contains a Yb fiber laser beam with a 
nominal diameter of 70 to 150 µm and maximum 
power of 150 W. Cylindrical specimens of 3 mm in 
diameter and height were manufactured. The porous 
Ti implants were solvent-cleansed by serial ultrasonic 
treatment in acetone, ethyl alcohol and de-ionized 
water. The 3D printed porous Ti implants were 
sterilized before coating by incubation in 70 % (v/v) 
ethanol for 30 min and then washed 5 times with 
distilled water. PLGA was dissolved in acetone to 
prepare 15 % PLGA-acetone solutions. To accelerate 
its dissolution in acetone, PLGA was stirred for 1 h. 
E-2,5-DHB in acetone was incorporated into the 
PLGA solution before coating. 3D printed porous 
Ti implants were immersed in the PLGA-acetone-E-
2,5-DHB solution for 5 min to force the solution into 
the porous structure. Then, the PLGA-coated 3D Ti 
implants were dried for 5 d to remove the residual 
acetone.
Characterization of the E-2,5-DHB-incorporating 
PLGA-coated titanium implants
Surface morphology of the Ti implants was observed 
with a field emission scanning electron microscope 
(FE-SEM S-800; Hitachi, Tokyo, Japan) using an 
accelerating voltage of 20 kV, as well as by micro-
computed tomography (µCT) (NFR Polaris-G90; 
NanoFocus Ray Co., Jeonju, Korea).
 E-2,5-DHB loading capacity was determined by 
measuring the concentration of coated E-2,5-DHB. 
The E-2,5-DHB-incorporating PLGA-coated Ti 
implants were immersed in DMSO. After vortexing, 
the solution was measured spectrophotometrically 
at 338 nm. To determine the release kinetics of 
E-2,5-DHB from the Ti implants, the E-2,5-DHB-
incorporating PLGA-coated Ti implants were 
immersed in 1 mL of phosphate-buffered saline (PBS) 
solution at 37 °C. At predetermined time intervals of 
1, 3 and 5 h and 1, 3, 7, 14, 21 and 28 d, the supernatant 
was collected and replaced with fresh PBS solution. 
The amount of E-2,5-DHB released in the collected 
solution was measured spectrophotometrically at 
240 nm.
In vivo bone healing in an osteoporotic animal 
model using 3D printed titanium implants coated 
with PLGA incorporated with E-2,5-DHB
All animal experiments were performed in accordance 
with the Korean Food and Drug Administration 
guidelines. Protocols were reviewed and approved 
by the Institutional Animal Care and Use Committee 
of the Yonsei Laboratory Animal Research Center 
(Permit No. 2015-0120). All animals were kept at 20-
26 °C under a 12 h light/dark cycle and allowed food 
and water ad libitum.
 20 female Sprague-Dawley rats (3 months old), 
which underwent several procedures during the 
course of the experiment (Fig. 1), were acclimatized 
for 1 week before the experiments. The animals were 
anesthetized by an intramuscular injection of Zoletil 
(30 mg/kg; MNS Korea, Kyungki Do, Korea) and 
Rompun (10 mg/kg; MNS Korea). The abdominal 
cavity was accessed by a 20 mm midline dorsal skin 
incision, which allowed for blunt dissection of the 
connective tissue between the skin and the muscular 
layer of the abdominal wall. The ovary was located 
in a fat pad and gently pulled outside the abdominal 
cavity. Two ligatures were placed with absorbable 4-0 
sutures. The ovaries were cut and removed and the 
uterine horns were placed back into the abdominal 
cavity. The abdominal muscles were closed with 
absorbable 4-0 sutures using a continuous suture 
technique, after which the skin was sutured with 
multiple single absorbable sutures. The animals 
were administered 1 mg/kg meloxicam and 5 mg/
kg gentamicin subcutaneously for postoperative 
analgesia and infection prophylaxis, respectively. 
The SHAM-operated group underwent the same 
surgical procedure as the ovariectomy (OVX) 
group, except their ovaries were not removed. After 
6 weeks, all animals were assessed for total body 
bone mineral density (BMD) using dual-energy 
X-ray absorptiometry (DXA; InAlyzer, Medikors, 
Seongnam, Korea) and µCT (NFR Polaris-G90, 
NanoFocus Ray Co.) to confirm the usefulness of the 
OVX group as a model of osteoporosis. The animals 
were also weighed weekly.
 Six weeks after the OVX or SHAM surgery, a 
femoral defect was created. The rats were divided into 
the following five groups: SHAM (sham-operation), 
OVX, OVX + Ti, OVX + Ti (1 mg) and OVX + Ti (2 mg). 
The OVX + Ti group received a Ti implant with only 
PLGA-coating, whereas the OVX + Ti (1 mg) and 
OVX + Ti (2 mg) groups received a Ti implant with 
PLGA-coating containing 1 mg and 2 mg of E-2,5-
DHB, respectively.
 The animals were anesthetized by an intramuscular 
injection of Zoletil and Rumpun. Both hind limbs of 
the rats were shaved. A longitudinal incision through 
the skin and the muscle was made on the medial 
surface of the femur. After exposure of the medial side 
of the distal femur, a bone defect 3 mm in diameter 
and 3 mm in depth was created perpendicular to the 
bone’s surface. To create the defect, a dental drill 
Initial E-2,5-DHB concentration (mg)
1 2
Measured concentration (mg) 1.1 ± 0.7 1.9 ± 2.2
Table 1. Ethyl-2,5-dihydroxybenzoate (E-2,5-DHB) concentration in the E-2,5-DHB-incorporating PLGA-
coated titanium implants. Data are shown as mean ± SD.
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carbon dioxide atmosphere incubator. To evaluate 
osteoprotegerin (OPG) and receptor activator of 
nuclear factor-kappa B ligand (RANKL) expression, 
MC3T3-E1 cells were seeded onto 6-well plates at 
2 × 105 cells/well density and cultured in the presence 
or absence of E-2,5-DHB at 5 and 10 μg/mL. After 
being cultured for 7 d, the cells were extracted by 
adding ice-cold radioimmunoprecipitation assay 
(RIPA) buffer. The cell lysates were centrifuged at 
14,000 ×g for 15 min at 4 °C. Protein determination 
was performed by Bradford assay according to 
the manufacturer’s protocol. Protein samples were 
separated by electrophoresis using a 12.5 % sodium 
dodecyl sulfate polyacrylamide (SDS-PAGE) gel 
and then transferred onto polyvinylidene difluoride 
membranes. The membranes were incubated 
overnight at 4 °C with a rabbit polyclonal anti-
OPG antibody (1 : 1000 dilution; ab183910, Abcam, 
Cambridge, UK), a mouse monoclonal anti-RANKL 
antibody (2 μg/mL; MAB6263, R&D system, 
Minneapolis, MN, USA) or a rabbit polyclonal anti-β-
actin antibody (1 : 1000 dilution; 4967S, Cell Signaling, 
Danvers, MA, USA). Finally, the membranes were 
incubated with a horseradish-peroxidase-conjugated 
secondary antibody [anti-mouse IgG (1 : 2000; 7076S, 
Cell Signaling) or anti-rabbit IgG (1 : 2000; 7074P2, 
Cell Signaling)]. Protein expression was detected 
by enhanced chemiluminescence (Cell Signaling). 
All bands were quantified using Image J software 
(National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
All results are expressed as the mean ± standard 
deviation (SD) of at least three determinations. 
Statistical analysis was performed by analysis of 
variance (ANOVA), using SPSS software (SPSS Inc. 
Chicago, IL, USA). Statistically significant values were 
defined as p < 0.05.
Results
Characterization of titanium implants containing 
E-2,5-DHB
To determine the loading efficacy of E-2,5-DHB, the 
concentration of E-2,5-DHB coating the Ti implants 
was measured (Table 1). Ti implants containing E-2,5-
DHB were loaded with different amounts of E-2,5-
DHB. The loading concentrations of E-2,5-DHB for 
the 1 mg and 2 mg implants were 1.1 mg and 1.9 mg, 
respectively.
 The surface morphology of the Ti implants 
was observed after PLGA coating (Fig. 2a). The 
prepared Ti implants had porous structures with 
open micropores ranging from 200 to 250 μm. 
After being coated with PLGA, the Ti implants 
still maintained a large pore structure. Scanning 
electron microscopy (SEM) images of the Ti implants 
revealed that their pore walls exhibited a surface with 
regular micropores. After being coated by PLGA, 
(Marathon-N1, Saeyang Co., Daegu, Korea) was 
used with constant saline cooling. The defects were 
irrigated with normal saline to remove bone residue. 
Then, the drilled cavity was washed with saline 
and dried using a sterile cotton gauze. Defects were 
made bilaterally and transplants were randomized. 
The defect was either left empty (as the control) or 
the 3D printed porous Ti implants were positioned 
within the cavity. The subcutaneous tissue layer was 
closed with absorbable 4-0 sutures, after which the 
skin was closed. Finally, the defects were covered by 
returning the quadriceps to their original position 
and repositioning the patella.
Dual-energy x-ray absorptiometry (DXA)
Bone mineral content (BMC) and BMD of the femur 
were assessed by DXA. All femora were evaluated 6 
weeks after the ovariectomy.
µCT analysis
At 4, 8 and 12 weeks following transplantation of Ti 
implants containing E-2,5-DHB into the OVX rats, 
the operated animals were scanned using a high 
resolution µCT imaging system. The animals were 
placed in a supine position onto the scan stage and 
sedated by inhalationof 2 % isoflurane. The following 
µCT settings were used: resolution 39 µm, tube 
voltage 65 kV, tube current 115 μA and exposure 
time 34 ms for each of the 360° rotational steps. The 
reconstruction image size was 1024 × 1024 pixels 
and the number of slices was 512. 3D models of the 
trabecular bones of the femur were reconstructed 
using the Lucion software (Mevisys, Seoul, Korea) 
to evaluate bone alterations. The µCT sagittal section 
through the midline of the defect was selected to 
measure each defect.
Histological analysis
Histology was performed on the femora of each 
group of animals to study the bone-Ti interface 
and bone morphology. After harvesting the femora 
and removing the surrounding soft tissues, the 
bones were fixed in 10 % neutral-buffered formalin 
solution, dehydrated in graded ethanol solutions 
ranging from 70 % to 100 % and then embedded in 
Technovit 7200 methacrylate resin (Heraeus Kulzer, 
Bad Sachsa, Germany). Sections of 40 ± 5 µm were 
obtained using an EXAKT diamond cutting system 
(EXAKT 300 CP, Bamberg, Germany) and stained 
with Goldner’s trichrome to study mineralization. 
The stained sections were observed using an optical 
microscope (BX51, Olympus, Tokyo, Japan).
Mechanism of osteoclast differentiation 
inhibition by E-2,5-DHB: western blot
MC3T3-E1 mouse preosteoblast cells were maintained 
in a α-MEM without ascorbic acid, supplemented 
with 10 % FBS and 1 % antibiotic and antimycotic 
solution. For all experiments, cells were used up to 
the 10th passage. They were grown at 37 °C in a 5 % 
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Fig. 2. Characterization of E-2,5-DHB-incorporating PLGA-coated Ti implants. (a) SEM images of Ti-only 
implants and PLGA-coated Ti implants. (b) E-2,5-DHB release kinetic from E-2,5-DHB-incorporating 
PLGA-coated Ti implants in PBS at 37 °C. The data are presented as mean ± SD (n = 4).
Fig. 3. Confirmation of the rat osteoporotic model. (a) The body weight of OVX rats was significantly 
larger than that of the SHAM control rats. (b) µCT: 2-dimensional (2D) and 3D images of distal femora 
from SHAM and OVX rats (scale bar = 500 µm) at 6 weeks.
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the Ti implants still maintained this pore structure. 
The coated-PLGA thickness was approximately 
10 ± 2 μm. Release profiles obtained after the release 
of E-2,5-DHB from E-2,5-DHB-incorporating PLGA-
coated Ti implants are shown in Fig. 2b. At day 7, 
the amount of E-2,5-DHB released from the implants 
containing 1 and 2 mg of E-2,5-DHB was 54 % and 
61 %, respectively. E-2,5-DHB released from the 
E-2,5-DHB-incorporating PLGA-coated Ti implants 
exhibited a burst release, with most of the drug being 
released within the first 7 d. Over the 28 d period, 
70 % of the E-2,5-DHB was released from both the 1 
and 2 mg E-2,5-DHB-incorporating PLGA-coated Ti 
implants, resulting in a sustained release profile.
Characterization of the osteoporosis animal 
model
Animals in the sham-operated group showed a 
steady increase in body weight during the 6 weeks 
observation period (Fig. 3a). Following ovariectomy, 
OVX rats weighed significantly more than SHAM rats 
at the evaluated time intervals. Initial body weights 
(221 ± 6 g) were similar among all rats. At the end of 
the 6 weeks period of osteoporosis induction, the final 
body weight was significantly higher in OVX rats 
(307 ± 6 g) than in SHAM rats (254 ± 6 g) (p < 0.01).
 6 weeks after the initial surgery, the mean femoral 
BMC was significantly lower in the OVX group than in 
the SHAM group: 0.101 ± 0.017 g and 0.107 ± 0.008 g, 
respectively (p < 0.05) (Table 2). Likewise, the mean 
BMD of the femur was significantly lower in the OVX 
group (0.347 ± 0.015 g/cm2) than in the SHAM group 
(0.374 ± 0.025 g/cm2) (p < 0.05).
 µCT analysis revealed structural differences 
between the OVX and SHAM groups with respect 
to the trabecular architecture of the femur (Fig. 3b).
Bone healing of femoral defects in ovariectomy 
rats
µCT images were acquired to analyze the morphology 
and mineralization of new bone formation within the 
femoral defects. As shown in Fig. 4a (representative 
longitudinal µCT images), in the E-2,5-DHB group, 
newly formed bone was more than in the control 
group. This confirmed healing of the defects in the 
presence of E-2,5-DHB. Much less mineralized tissue 
was present in the untreated defects. A minimal 
amount of new bone formation was found in the 
only-PLGA-coated Ti group at all time intervals 
considered. The E-2,5-DHB-coated Ti groups 
exhibited the largest amounts of mineralized bone.
 The bone newly formed in the Ti implant area 
after 3 months was assessed by PACS software, which 
measures bone density in Hounsfield units (HU) 
(Fig. 4b). Values obtained from µCT scans taken 4, 
8 and 12 weeks postoperatively were compared and 
revealed the type of bone formed in the vicinity of 
the implant. Radiological evaluations using µCT 
scans showed a substantial increase in bone volume 
in the regions implanted with E-2,5-DHB after 12 
weeks. The bone formed around the implant was 
more bone regeneration, with higher HU values. 
The enhancement of bone formation 8 and 12 weeks 
postoperatively in the E-2,5-DHB-coated Ti groups 
was superior (with higher HU values) compared 
to the only-PLGA-coated Ti group. HU values 
increased by 167 % and 144 % at 8 weeks and 12 
weeks, respectively, in the E-2,5-DHB (1 mg) group 
and 154 % and 144 % in the E-2,5-DHB (2 mg) group. 
In the only-PLGA-coated group, the volume of 
bone formed was less compared to the successfully 
implanted E-2,5-DHB-coated group areas, with low 
HU values  and signifying poor quality of formed 
bone. Moreover, as shown in Fig. 4c, no defect healing 
was observed in the defect area of osteoporotic rats 
during the transplantation period.
Histology analysis
Histologic findings (Goldner’s trichrome staining) 
at the fracture sites supported the biomechanical 
evidence of accelerated defect healing by the released 
E-2,5-DHB (Fig. 5). Areas of newly formed bone, 
stained blue, differed considerably and only-PLGA-
coated Ti implants showed less bone than E-2,5-DHB-
coated Ti implants (1 mg and 2 mg). Bone formation 
inside the porous space was mainly located at distal 
sites and resulted in direct bone-Ti contact. Direct 
bone-Ti contact was found throughout the entire 
bone-Ti interface. Trabecular bone areas around 
the E-2,5-DHB-coated Ti implants in animals were 
connected and more newly formed bone was seen 
in direct contact with the E-2,5-DHB coated surface 
compared with the only-PLGA-coated control 
implants.
 Infiltration of newly formed bone was observed 
inside the pores filled with newly formed bone and 
within the Ti implants (Fig. 6a). Image J analysis 
showed that the result was not statistically significant, 
but the area of positive staining in animals with E-2,5-
DHB coated Ti implants was large. Quantification 
of the Goldner’s trichrome staining images revealed 
differences between the only-PLGA-coated Ti 
group and the E-2,5-DHB-coated Ti groups, as the 
defects revealed less staining in the only-PLGA-
coated control animals. The amount of bone around 
only-PLGA-coated Ti implants in osteoporotic rats 
Table 2. Confirmation of the rat osteoporotic model. Femur BMC and BMD were significantly lower in 
the OVX group compared to the SHAM group. Data are shown as mean ± SD.
SHAM OVX
BMC (g) 0.107 ± 0.008 0.101 ± 0.017
BMD (g/cm2) 0.374 ± 0.025 0.347 ± 0.015
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was smaller with respect to the E-2,5-DHB-coated 
groups (Fig. 6b). Statistically, the positive staining 
area percentage was significantly larger in the E-2,5-
DHB-coated Ti group than in the only-PLGA-coated 
Ti group.
Inhibition of osteoclast differentiation by E-2,5-
DHB
E-2,5-DHB treatment inhibits osteoclast differentiation 
(Kwon et al., 2016). To investigate the mechanism of 
inhibition of osteoclast differentiation, OPG and 
RANKL expression were measured. The concerted 
actions of OPG, receptor activator of nuclear factor-
kappa B (RANK), and RANKL play a central role 
in maintaining the delicate balance between bone 
resorption and formation and in preserving bone 
mass (Boyle et al., 2013; Khosla et al., 2001; Hofbauer 
and Schoppet, 2004). To investigate the effect of 
E-2,5-DHB on OPG and RANKL expression, which 
are synthesized by osteoblasts, MC3T3-E1 cells were 
treated with E-2,5-DHB and OPG and RANKL protein 
levels were measured by western blot analysis (Fig. 
7). The results indicated that expression of RANKL at 
the protein level was downregulated by E-2,5-DHB, 
whereas OPG levels were significantly upregulated. 
These results suggested that E-2,5-DHB (5 and 10 μg/
mL) was more effective in stimulating the secretion of 
OPG as opposed to RANKL, thus exerting inhibitory 
effects on osteoclast differentiation.
Discussion
The aim of this study to investigate the effect of 
E-2,5-DHB on bone defects healing in osteoporotic 
conditions. The results confirmed the ability of E-2,5-
DHB-incorporating Ti implants using PLGA coating 
for local delivery of E-2,5-DHB to enhance fracture 
healing in osteoporotic bones.
 Using conventional fabrication techniques, it is 
difficult to adjust the internal pore size, geometry and 
distribution (Pattanayak et al., 2009; Yang et al., 2000). 
In contrast, the SLM process is an effective technique 
for fabricating 3D porous structures directly from 
metal powders. Consequently, the process is suitable 
for designing artificial bone substitutes with complex 
inner and outer geometries that will fit a patient’s 
defective bone. In this study, 3D printed Ti implants 
with pore sizes of 200 to 250 µm were prepared. 
These implants were coated with a PLGA surface 
layer. PLGA coating did not decrease the pore size 
of the Ti implants. The small pore size benefits cell 
ingrowth and enhances diffusion of nutrients into the 
3D scaffolds (Barou et al., 2002). Our results suggested 
that PLGA modification was a viable method to 
improve the physicochemical and drug-delivery 
properties of the Ti implants.
 BMC and BMD at the femur site of OVX rats 
were shown to be decreased at week 6 post-surgery, 
when compared to the SHAM group. µCT images 
Fig. 4. Bone healing of femoral defects in OVX rats. (a) Representative µCT images of the distal femur 
showing mineralized bone formation within defects in the control (CON) group, titanium (Ti) + 1 mg 
E-2,5-DHB group and Ti + 2 mg E-2,5-DHB group, 12 weeks after surgery. The CON group received a Ti 
implant coated with only PLGA. Scale bar = 5 mm. (b) Quality of bone formed in the Ti implant area 3 
months postoperatively was assessed by PACS software (Piviewer, INFINITT Healthcare, Seoul, Korea), 
which measures bone density in Hounsfield units. Data are shown as mean ± SD (* p < 0.05 compared with 
the Ti group). (c) Representative µCT images of the distal femur showing mineralized bone formation 
within empty defect at 12 weeks. Scale bar = 5 mm.
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of the OVX rats confirmed a decrease in trabecular 
bone density, volume and thickness. OVX rats are 
commonly accepted as a suitable preclinical animal 
model for human postmenopausal osteoporosis (Jee 
and Yao, 2001; Lelovas et al., 2008; Turner, 2001). 
Similarly to previously published studies (Jee and 
Yao, 2001; Kalu, 1991; Lelovas et al., 2008; Turner, 
2001), our results indicated that over the course of 
the experiment, OVX rats presented most of the 
characteristics observed in human postmenopausal 
osteoporosis. This included a significant decrease in 
trabecular bone thickness and mass and an increase 
in trabecular spacing, compared to healthy (SHAM 
group) animals.
 Drugs can be administrated locally or systemically. 
Drugs delivered systemically are absorbed into the 
bloodstream and spread throughout the body by 
the circulatory system. This can lead to kidney and 
liver complications, lack of penetration into targeted 
tissues, systemic toxicity, as well as hospitalization 
of the patient. On the other hand, when the drug 
is delivered locally, the risk of side effects and 
overdosage, as for the systemic administration, 
may be limited and a high concentration of drug 
can effectively reach the target site (Price et al., 1996; 
Ruszczak and Friess, 2003; Somayaji et al., 1998). Local 
delivery is expected to increase the availability and 
efficacy of these bone anabolic or antiresorptive drugs 
and reduce the adverse effects associated with their 
tissue administration.
 Reports of previous studies evaluate treatments to 
enhance new bone formation or suppress excessive 
bone resorption during bone regeneration, such 
as estrogen, parathyroid hormone (PTH), selective 
estrogen receptor modulators, strontium ranelate, 
calcitonin, bisphosphonates, sclerostin antibodies and 
Dickkopf-1 antibodies (Agholme et al., 2011; Cao et 
al., 2002; Li et al., 2007; Nozaka et al., 2008). However, 
antiosteoporotic drugs (i.e. bisphosphonates and 
RANKL inhibitors) often reduce new bone formation 
because they disrupt the linkage between osteoclast 
and osteoblast activity. PTH is an anabolic drug that 
can directly stimulate bone formation and, currently, 
it is the only anabolic agent approved for osteoporosis 
treatment by the Food and Drug Administration 
(Tashjian and Gagel, 2006). However, the anabolic 
effects of PTH are usually related to enhanced bone 
resorption and withdrawal of PTH associates with 
loss of its therapeutic effects (Tanizawa et al., 1998). 
Strontium ranelate is one of the agents reported to 
facilitate osteoporotic fracture healing, exhibiting 
the dual effects of promoting bone formation and 
inhibiting bone resorption (Bonnelye et al., 2008; 
Goldberg et al., 1985; Habermann et al., 2010). Results 
of the current study showed that E-2,5-DHB, similar 
to strontium ranelate, could also be used as an 
effective agent to promote bone fracture healing in 
osteoporotic conditions.
 No signs of foreign body reactions or inflammatory 
responses were observed in our rat model. Porous 
titanium implants have recently received increased 
attention as a new biomaterial that can act as an 
osteoconductive scaffold, providing direct mechanical 
support in large bone defects at weight-bearing sites 
(Murr et al., 2010). However, they remain bioinert and, 
thereby, lack the ability to provide strong biological 
cues that enhance bone regeneration. This led to the 
hypothesis that E-2,5-DHB incorporated into porous 
Fig. 5. Representative Goldner’s trichrome staining of femur defects areas from SHAM, OVX and Ti 
implant groups at 12 weeks, respectively. The SHAM group underwent sham surgery; the OVX group 
underwent ovariectomy but received no implant; the Ti groups underwent ovariectomy and received 
implants containing PLGA coating only (CON group), 1 mg of E-2,5-DHB in PLGA (1 mg group) or 2 mg 
of E-2,5-DHB in PLGA (2 mg group). Scale bars = 1000 µm.
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Ti implants would result in a biologically active and 
mechanically strong composite biomaterial that 
would enhance bone healing of large bone defects.
 Ideal orthopedic scaffolds should be biocompatible 
with surrounding cells to expedite satisfactory bone 
attachment between implants and surrounding bone 
structures (Borsari et al., 2009). It is well known that 
successful implant fixation is closely related to the 
parallelism of the bone structure near the implant 
and the thickness of the bone (Brånemark et al., 1997).
 Additional bones formed around and near the 
implant, due to E-2,5-DHB elution, can be helpful 
in a wide range of orthopedic implant applications 
for increasing the reliability and accuracy of the 
device stability. Our results showed that local 
release of E-2,5-DHB directly from the implant had 
a positive effect on bone healing, while avoiding the 
disadvantages of systemic exposure.
 Some herbal medicines are reported to be effective 
in treating various diseases. Local administration 
of 4-herb formula (CDNR) controls inflammation 
and promotes bone regeneration (Siu et al., 2015). 
Other studies report the prevention and treatment 
of osteoporosis using plant-derived natural products 
(Caichompoo et al., 2009; Jeong et al., 2005; Ha et 
al., 2003; Kim et al., 2008; Li et al., 2012; Suh et al., 
2007). Lycii radicis cortex (LRC) extract may be a 
good natural herbal medicine candidate for the 
treatment of osteoporosis (Park et al., 2014) and for 
increasing spinal BMD (Wang et al., 2013). However, 
these studies evaluate the efficacy of herb extract 
as a drug to prevent osteoporosis and the effect of 
healing on osteoporotic defects is not evaluated. In 
the current study, unlike other herbal extras, E-2, 
5-DHB showed a dual action on osteoblasts and 
osteoclasts, demonstrating bone defect healing effect 
in osteoporotic conditions.
 Osteoclasts originate from the monocyte/
macrophage hematopoietic lineage and are 
responsible for bone resorption (Boyle et al., 2003; 
Zhao et al., 2007). RANKL, expressed by osteoblasts, 
plays a key role in the activation of osteoclasts by 
binding to the RANK receptor (Jimi et al., 1999). 
OPG, produced by osteoblasts, inhibits osteoclast 
differentiation by binding to RANKL (Hofbauer and 
Heufelder, 2000). The inhibitory effects of E-2,5-DHB 
on osteoclast differentiation are likely regulated 
by various paracrine factors, including OPG and 
RANKL, released from osteoblasts. In this study, 
it was demonstrated that E-2,5-DHB mediated an 
increase in the levels of secreted OPG, whereas 
it decreased RANKL levels. This suggested that 
E-2,5-DHB could affect the balance of OPG/RANKL 
pathway and promote bone healing in osteoporotic 
conditions.
Fig. 6. Goldner’s trichrome staining was analyzed by Image J software. For each sample, a circular region 
of the same size was chosen: (a) a circle with a diameter of 3 mm including the entire implant structure 
and (b) a 0.3 mm-thick ring of surrounding bone tissue. Data are shown as mean ± SD. * p < 0.1 compared 
to the Ti group in (b).
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Conclusion
E-2,5-DHB-incorporating PLGA-coated Ti discs 
were prepared and whether this could influence 
osteoblast functions, as well as inhibit osteoclast 
differentiation, was evaluated. Subsequently, the 
local release of E-2,5-DHB from E-2,5-DHB-coated Ti 
implants was used to enhance bone formation around 
implants inserted into femoral defects. This study 
demonstrated that local treatment with E-2,5-DHB 
resulted in significantly more new bone formation in 
the rat femur deficient area compared to the control 
(PLGA-coated only Ti disc). Comparing the total 
new bone formation, it was revealed that both 1 and 
2 mg of E-2,5-DHB induced significantly more bone 
formation. Therefore, it appeared that E-2,5-DHB-
coated Ti implants have great potential as an ideal 
local drug delivery system when using bone tissue 
scaffolds.
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Discussion with Reviewer
Wing Hoi Cheung: What is the potential to translate 
E-2,5-DHB-incorporating titanium implant for the use 
in clinical application?
Authors: E-2,5-DHB-incorporating titanium implants 
showed promising clinical potential, enhancing 
implant performance in the osteoporotic bone 
condition. In recent year, there has been an increasing 
effort to restore bone defects in patients with 
osteoporosis. Also, E-2,5-DHB-incorporating titanium 
implants showed great potential for implant surface 
coating in several clinical applications, including 
dental, plastic and orthopedic surgery.
Wing Hoi Cheung: Is there any side effect of E-2,5-
DHB?
Authors: E-2, 5-DHB is a derivative of Rubus coreanus 
extract, which does not represent a serious concern for 
safety since it is used as health food supplements. No 
serious adverse events, such as foreign body reactions 
or inflammatory reactions, have been observed in 
our rat model. Nevertheless, any side effect during 
clinical applications need to be confirmed.
Editor’s note: The Scientific Editor responsible for 
this paper was Chris Evans.
